Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal ETS2 Primary Antibody for FACS, IHC (p) - ABIN653803
Kabbout, Garcia, Fujimoto, Liu, Woods, Chow, Mendoza, Momin, James, Solis, Behrens, Lee, Wistuba, Kadara: ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Human Monoclonal ETS2 Primary Antibody for IHC, WB - ABIN2720577
Wang, Huang, Liu, Cai, Millard, Wang, Chang, Peng, Fan: Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. in Journal of molecular and cellular cardiology 2014
results demonstrate that PntP1 prevents both the premature differentiation and the dedifferentiation of INPs by regulating the expression of distinct target genes at different stages of imINP development.
Both PntP1 and PntP2 are required for oenocyte specification. Since PntP1 is a downstream effector of EGF (show EGFR Antibodies) signaling, these findings provide insight into how a Hox factor can both trigger and potentiate the EGF (show EGFR Antibodies) signal to promote an essential cell fate along the body plan.
PntP2 transcription factor plays a role in air sac (show ADCY10 Antibodies) development by regulation of the EGF (show EGFR Antibodies) ligand Vein protein.
These studies identify Cic (show CIC Antibodies), Pnt, and Ets21C as critical downstream effectors of EGFR (show EGFR Antibodies) signaling in Drosophila Intestinal Stem Cells
Btd (show BTD Antibodies) prevents the premature differentiation by suppressing the expression of Prospero (show PROX1 Antibodies) in immature intermediate neural progenitor cells. Btd (show BTD Antibodies) functions cooperatively with Pointed P1 to promote the generation of the above cells.
instances of co-expressed Yan and Pnt-GFP in tissues with high RTK signaling cannot be explained by the current model, and thus they provide important contexts for future investigation of how context-specific differences in RTK signaling
Data show that Appl (show APP Antibodies) is directly regulated by the Ras/MAPK (show MAPK1 Antibodies) pathway through a mechanism mediated by PntP2.
Specific disruption of either pntP1 or pntP2 resulted in the same R8-only phenotype, demonstrating that both Pnt isoforms are essential for photoreceptor recruitment
a low level of Notch (show NOTCH1 Antibodies) signaling functions to maintain the neuroepithelial cell identity by suppressing the expression of pointedP1 gene through the transcriptional repressor Anterior open.
Demonstrate that the Pointed-P2 PNT domain contains a dynamic N-terminal helix H0 appended to a core conserved five-helix bundle diagnostic of the SAM (show TTN Antibodies) domain fold.
Homozygous deletion of Ets2 in p53 (show TP53 Antibodies) mutant mice resulted in strong down-regulation of snoRNAs and reversed the prometastatic phenotype of mutant p53 (show TP53 Antibodies) but had no effect on osteosarcoma development, which remained 100% penetrant.
These results suggest an unappreciated role for ETS2 in fibroblasts in establishing an immune-suppressive microenvironment in response to oncogenic Kras(G12D) signaling during the initial stages of tumor development.
The differentiation of ERF-overexpressing trophoblast stem cell lines also suggests that ERF may have an FGF2 (show FGF2 Antibodies)-independent effect during the commitment towards syncytiotrophoblasts.
MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformation
Elf5 (show ELF5 Antibodies) and Ets2 have roles in maintaining the mouse extraembryonic ectoderm in a dosage dependent synergistic manner
identified Ets2 as a key novel regulator in both the positive and negative control of miR (show MLXIP Antibodies)-155 in the inflammatory response.
The data reveals a key function for Ets2 in tumor fibroblasts in signaling to endothelial cells to promote tumor angiogenesis.
Data indicate that differences between the N termini of transcription factors Ets1 (show ETS1 Antibodies) and Ets2, rather than differences in the DNA binding domains, determine whether the proteins are capable of blocking antibody-secreting cells (ASCs) formation or not.
propose a model that provides a genetic explanation as to how Ets2 in trophoblast mediates the progression of gastrulation within the epiblast
Ets-2 play a key role in transcriptional regulation of CTRP5 (show C1QTNF5 Antibodies) in muscle cells.
ETS2 is of potential value as a molecular target for RCC (show XRCC1 Antibodies) treatment.
ETS2 functions as an oncogene (show RAB1A Antibodies) and plays a key role in the progression of hypopharyngeal cancer.
ETS2 (high) is a poor prognostic factor in acute myeloid leukemia and may guide treatment decisions towards allogeneic hematopoietic stem cell transplantation.
Findings strongly suggest a critical role of Ets2 in human esophageal squamous cell carcinoma pathogenesis via the inactivation of the mTOR (show FRAP1 Antibodies)/p70S6K (show RPS6KB1 Antibodies) signaling pathway.
Authors demonstrate that mtp53 prevents the COP1 (show CARD16 Antibodies)/DET1 complex from ubiquitinating ETS2 and thereby marking it for destruction. Authors show that mtp53 destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing ETS2 degradation.
These findings suggest that ETS2 rs461155A>G, could be used as a biomarker predicting the clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Interaction with ZMYND11 (show ZMYND11 Antibodies) mediates opposing roles of Ras-responsive ETS1 (show ETS1 Antibodies) and ETS2.
Data suggest marked changes in DNA methylation (show HELLS Antibodies) occur at a single CpG site (CpG4) in promoter region of ESR1 (show ESR1 Antibodies) as breast cancer cells become resistant to hormonal/aromatase (show CYP19A1 Antibodies) inhibitor antineoplastic agents; this CpG region is completely conserved among species, suggesting that it acts as a methylation-sensitive ETS2 transcription factor binding site/response element. (ESR1 (show ESR1 Antibodies) = estrogen receptor 1 (show ESR1 Antibodies); ETS2 = ETS (show ETS1 Antibodies) proto-oncogene (show RAB1A Antibodies) 2)
ETS2 and Twist1 (show TWIST1 Antibodies) promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2 (show SIAH2 Antibodies)
DLX3 has a central role in controlling IFNT gene expression by associating with ETS2 on the IFNT promoter.
This gene encodes a transcription factor which regulates genes involved in development and apoptosis. The encoded protein is also a protooncogene and shown to be involved in regulation of telomerase. A pseudogene of this gene is located on the X chromosome. Alternative splicing results in multiple transcript variants.
, Ets at 58AB
, Ets protein pointed P2
, no terminal cell clones-R
, pointed P2
, avian leukemia oncogene 2
, protein C-ets-2
, oncogene ETS-2
, v-ets avian erythroblastosis virus E2 oncogene homolog 2
, v-ets erythroblastosis virus E26 oncogene homolog 2
, E26 avian leukemia oncogene 2, 3' domain
, avian erythroblastosis virus E26 (v-ets) oncogene homolog 2
, v-ets avian erythroblastosis virus E26 oncogene homolog 2